下肢血运重建后启用5-羟色胺能抗抑郁药与血小板抑制波动增加相关
本研究为单中心回顾性队列研究,纳入514例下肢血运重建的外周动脉疾病患者,其中330例贡献896对连续随访数据,分析5-羟色胺能抗抑郁药暴露与ADP介导血小板抑制纵向变异性的关联。结果发现药物启用(而非稳定暴露)与血小板抑制波动增加独立相关,在慢性肢体威胁性缺血亚组中启用还与ADP介导血小板抑制平均上移19.7个百分点相关。
要点
- 稳定使用5-羟色胺能抗抑郁药未显示与血小板抑制变异性增加独立相关
- 新启用5-羟色胺能抗抑郁药与ADP介导血小板抑制波动增加相关,需关注启用前后窗口
- 替格瑞洛使用与更低的血小板抑制变异性独立相关
核心结论
- 下肢血运重建后启用5-羟色胺能抗抑郁药(而非稳定持续治疗)与ADP介导血小板抑制不稳定性增加相关。
- 启用前后的窗口期对血管外科患者用药核对具有意义,并提示背景P2Y12方案一致性可能调节该不稳定性幅度。
研究设计与样本
- 单中心、美国三级医疗中心、回顾性队列研究,患者来自前瞻性入组的下肢血运重建外周动脉疾病患者(2020年12月至2025年)。
- 514例入组病例中330例贡献896对连续随访数据;完整病例校正分析中307例贡献838对连续随访数据。
- 使用连续血栓弹力图血小板分布图数据构建连续随访配对,以相邻测量间对数转换绝对变化定义访视间变异性。
临床怎么用
- 对下肢血运重建后拟启用5-羟色胺能抗抑郁药的患者,应在启用前后加强血小板功能与出血/缺血风险评估。
- 用药核对时应关注抗抑郁药启用状态及P2Y12抑制剂方案的一致性,而非仅关注是否长期服用。
局限性
- 单中心回顾性设计,暴露与结局关联可能受未测量混杂影响。
- 完整病例校正分析样本量小于总入组病例,可能存在选择偏倚。
- 慢性肢体威胁性缺血分析为预设探索性分析,结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Depression affects 20% to 37% of patients with peripheral artery disease, frequently requiring serotonergic antidepressants while receiving antiplatelet therapy concomitantly after vascular intervention. As platelets depend entirely on the serotonin transporter for serotonin uptake, serotonergic agents may alter platelet function in this setting. Hence, we aimed to determine whether serotonergic antidepressant exposure is associated with longitudinal instability in adenosine diphosphate (ADP)-mediated platelet inhibition. METHODS: In this retrospective cohort study of prospectively enrolled patients with peripheral artery disease undergoing lower-extremity revascularization (December 2020-2025) at a single US tertiary care center, serial thromboelastography with platelet mapping data (December 2020-2025) were used to construct consecutive-visit pairs. The primary outcome was visit-to-visit variability in ADP-mediated platelet inhibition, defined as log-transformed absolute change between consecutive measurements, capturing larger visit-to-visit change regardless of direction. Serotonergic antidepressant exposure (such as selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, or trazodone) was evaluated both as active exposure at the current assessment within each consecutive measurement pair and as a four-level transition variable: stable nonexposure ((0→0), reference), initiation (0→1, exposure onset between two sequential assessments), discontinuation (1→0), and stable exposure (1→1). Associations were estimated using adjusted linear mixed-effects model. Prespecified exploratory analyses were performed in the chronic limb-threatening ischemia subgroup. RESULTS: Among 514 enrolled cases, 330 contributing 896 consecutive-visit pairs were included; 307 patients contributed 838 consecutive-visit pairs in the complete case-adjusted analysis. Active serotonergic exposure was not independently associated with greater longitudinal variability in platelet inhibition [β = .135; 95% confidence interval (CI), -0.901 to 0.360; P = .240]. However, serotonergic initiation was associated with increased variability compared with stable nonexposure (β = .571, 95% CI, 0.144-0.998; P = .009), persisting after adjustment for psychiatric diagnosis burden. Discontinuation showed a borderline association (β = .405; P = .05); stable exposure was not associated with greater variability (β = .105; P = .40). Ticagrelor use was independently associated with lower variability in primary adjusted models (β = -.521; 95% CI, -0.901 to -0.141; P = .008). In exploratory chronic climb-threatening ischemia analyses, initiation was associated with a 19.7 percentage point mean upward shift in ADP-mediated platelet inhibition (95% CI, 3.9-35.6; P = .015) and higher odds of entering a high-inhibition range previously linked to bleeding risk (odds ratio, 7.61; 95% CI, 1.32-43.96; P = .023). CONCLUSIONS: Serotonergic antidepressant initiation, rather than stable ongoing therapy, was associated with increased instability in ADP-mediated platelet inhibition after lower-extremity revascularization. These findings identify the peri-initiation window with implications for medication reconciliation in vascular surgery patients and raise the hypothesis that background P2Y12 regimen consistency may modulate the magnitude of serotonergic medication-induced platelet instability.
引用
- Bansal R, Fouzdar S, Bhatt S, et al. Serotonergic antidepressant initiation associated with increased platelet inhibition variability after lower-extremity revascularization. J Vasc Surg. 2026. PMID: 42480630. doi:10.1016/j.jvs.2026.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。